Lactic Acid Bacteria for Reducing Blue Light-Induced Eye Fatigue
The Application of Lactic Acid Bacteria on Reducing Blue Light-Induced Eye Fatigue in Middle-Aged Adults
1 other identifier
interventional
150
1 country
1
Brief Summary
With the widespread use of digital devices and prolonged screen exposure, digital eye strain (DES), also known as computer vision syndrome, has become a global public health concern. Emerging evidence suggests that the gut-eye axis may play an important role in ocular health, as gut microbiota imbalance is associated with systemic inflammation and oxidative stress. Specific probiotics may help alleviate eye discomfort through modulation of immune responses and enhancement of antioxidant defense mechanisms. This randomized, double-blind, placebo-controlled study aims to evaluate the efficacy of supplementation with specific probiotics, Bifidobacterium longum BL531 and Lactobacillus reuteri LR1349, in improving digital eye strain symptoms in adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 27, 2026
CompletedFirst Posted
Study publicly available on registry
July 30, 2026
CompletedStudy Start
First participant enrolled
September 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2027
Study Completion
Last participant's last visit for all outcomes
December 31, 2027
July 30, 2026
July 1, 2026
12 months
July 27, 2026
July 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Computer Vision Syndrome Questionnaire (CVS-Q)
The CVS-Q is a questionnaire used to assess digital eye strain associated with prolonged digital screen use. It includes 16 symptoms related to screen exposure. Total scores are classified as 0-5 (none/minimal), 6-12 (mild), 13-18 (moderate), and ≥19 (severe), with scores ≥6 indicating clinically significant digital eye strain.
Baseline, Week 6, Week 12
Secondary Outcomes (8)
Ocular Surface Disease Index (OSDI)
Baseline, Week 6, Week 12
Basic vision examination
Baseline and Week 12
Pupillary Response Test
Baseline and Week 12
Tear Secretion Assessment
Baseline and Week 12
Non-Invasive Tear Break-Up Time (NIBUT)
Baseline and Week 12
- +3 more secondary outcomes
Study Arms (5)
Placebo
PLACEBO COMPARATORSubjects assigned to the placebo group will take one placebo capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.
BL531_low dose
EXPERIMENTALSubjects assigned to each intervention group will take one capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.
BL531_high dose
EXPERIMENTALSubjects assigned to each intervention group will take one capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.
LR1349_low dose
EXPERIMENTALSubjects assigned to each intervention group will take one capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.
LR1349_high dose
EXPERIMENTALSubjects assigned to each intervention group will take one capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.
Interventions
Eligibility Criteria
You may qualify if:
- Men and women aged 20-65 years
- Daily digital screen use \>6 hours for at least 1 year
- Mild to severe digital eye strain (CVS-Q score ≥ 6)
- Mild to moderate dry eye symptoms (OSDI ≥ 13)
You may not qualify if:
- Amblyopia or strabismus
- Severe eye diseases (e.g., glaucoma , cataract , retinal disorders, severe corneal disease)
- Ocular surgery within the past 12 months
- Chronic systemic diseases (e.g., uncontrolled diabetes, autoimmune disease, severe liver/kidney impairment, cancer)
- Recent use (\<1 months) of steroids, antibiotics, immunosuppressants, probiotics, prebiotics, or eye-health supplements
- Pregnant or breastfeeding
- Allergy to probiotics or study product ingredients
- Eating disorders, psychiatric illness, or cognitive impairment affecting compliance
- Any condition judged unsuitable by the investigator
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Synbio Tech Inc.lead
Study Sites (1)
National Taiwan Normal University
Taipei, 106, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 27, 2026
First Posted
July 30, 2026
Study Start (Estimated)
September 1, 2026
Primary Completion (Estimated)
August 31, 2027
Study Completion (Estimated)
December 31, 2027
Last Updated
July 30, 2026
Record last verified: 2026-07